Novocure Stock Buy Hold or Sell Recommendation
| NVCR Stock | USD 12.02 0.03 0.25% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Novocure is 'Sell'. Macroaxis provides Novocure buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Novocure positions. The advice algorithm takes into account all of Novocure's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Novocure's buy or sell advice are summarized below:
Real Value 11.62 | Target Price 56.57 | Hype Value 12.05 | Market Value 12.02 | Naive Value 11 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Novocure given historical horizon and risk tolerance towards Novocure. When Macroaxis issues a 'buy' or 'sell' recommendation for Novocure, the advice is generated through an automated system that utilizes algorithms and statistical models.
Novocure |
Execute Novocure Buy or Sell Advice
The Novocure recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Novocure. Macroaxis does not own or have any residual interests in Novocure or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Novocure's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Novocure Trading Alerts and Improvement Suggestions
| Novocure generated a negative expected return over the last 90 days | |
| Novocure has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 509.34 M. Net Loss for the year was (207.04 M) with profit before overhead, payroll, taxes, and interest of 423.58 M. | |
| Novocure currently holds about 948.52 M in cash with (73.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.06. | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 7693 shares by Moshe Giladi of Novocure at 83.77 subject to Rule 16b-3 |
Novocure Returns Distribution Density
The distribution of Novocure's historical returns is an attempt to chart the uncertainty of Novocure's future price movements. The chart of the probability distribution of Novocure daily returns describes the distribution of returns around its average expected value. We use Novocure price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Novocure returns is essential to provide solid investment advice for Novocure.
| Mean Return | -0.05 | Value At Risk | -6.26 | Potential Upside | 9.01 | Standard Deviation | 4.75 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Novocure historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Novocure Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Novocure is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Novocure backward and forwards among themselves. Novocure's institutional investor refers to the entity that pools money to purchase Novocure's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nordwand Advisors Llc | 2023-12-31 | 1.5 M | Two Sigma Investments Llc | 2023-12-31 | 1.5 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.4 M | Millennium Management Llc | 2023-12-31 | 1.1 M | Norges Bank | 2023-12-31 | 974 K | Credit Suisse First Boston (csfb) | 2023-12-31 | 853.5 K | Frontier Capital Management Co Inc | 2023-12-31 | 793.5 K | Qube Research & Technologies | 2023-12-31 | 773.8 K | Bank Of America Corp | 2023-12-31 | 678.6 K | Fmr Inc | 2023-12-31 | 16 M | Vanguard Group Inc | 2023-12-31 | 9.8 M |
Novocure Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (1.2M) | (2.9M) | 2.5M | (4.3M) | (8.9M) | (8.5M) | |
| Investments | (41.2M) | (457.9M) | (120.7M) | (140.0M) | (42.4M) | (44.5M) | |
| Change In Cash | 36.7M | 66.8M | (36.6M) | (93.8M) | 126.7M | 133.1M | |
| Net Borrowings | (31K) | 408.4M | (26K) | (28K) | (32.2K) | (30.6K) | |
| Free Cash Flow | 16.1M | 84.2M | 58.6M | 9.4M | (100.4M) | (95.4M) | |
| Depreciation | 8.5M | 9.2M | 10.3M | 10.6M | 11.0M | 7.8M | |
| Other Non Cash Items | (2.2M) | 3.3M | 3.0M | (6.1M) | (23.2M) | (22.0M) | |
| Capital Expenditures | 10.5M | 15.0M | 24.2M | 21.4M | 27.1M | 14.6M | |
| Net Income | (7.2M) | 19.8M | (58.4M) | (92.5M) | (207.0M) | (196.7M) | |
| End Period Cash Flow | 179.4M | 246.2M | 209.6M | 115.8M | 242.6M | 166.8M | |
| Change To Netincome | 51.9M | 75.5M | 101.8M | 104.7M | 120.4M | 126.4M | |
| Change Receivables | (36.5M) | (30.4M) | 5.3M | 2.5M | 2.9M | 3.1M |
Novocure Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Novocure or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Novocure's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Novocure stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.23 | |
β | Beta against NYSE Composite | 3.78 | |
σ | Overall volatility | 4.28 | |
Ir | Information ratio | -0.02 |
Novocure Volatility Alert
Novocure exhibits very low volatility with skewness of 1.05 and kurtosis of 1.74. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Novocure's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Novocure's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Novocure Implied Volatility
Novocure's implied volatility exposes the market's sentiment of Novocure stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Novocure's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Novocure stock will not fluctuate a lot when Novocure's options are near their expiration.
Novocure Fundamentals Vs Peers
Comparing Novocure's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Novocure's direct or indirect competition across all of the common fundamentals between Novocure and the related equities. This way, we can detect undervalued stocks with similar characteristics as Novocure or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Novocure's fundamental indicators could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Novocure to competition |
| Fundamentals | Novocure | Peer Average |
| Return On Equity | -0.52 | -0.31 |
| Return On Asset | -0.12 | -0.14 |
| Profit Margin | (0.41) % | (1.27) % |
| Operating Margin | (0.34) % | (5.51) % |
| Current Valuation | 1.03 B | 16.62 B |
| Shares Outstanding | 107.09 M | 571.82 M |
| Shares Owned By Insiders | 1.66 % | 10.09 % |
| Shares Owned By Institutions | 85.87 % | 39.21 % |
| Number Of Shares Shorted | 5.01 M | 4.71 M |
| Price To Earning | 721.15 X | 28.72 X |
| Price To Book | 4.01 X | 9.51 X |
| Price To Sales | 2.85 X | 11.42 X |
| Revenue | 509.34 M | 9.43 B |
| Gross Profit | 423.58 M | 27.38 B |
| EBITDA | (176.66 M) | 3.9 B |
| Net Income | (207.04 M) | 570.98 M |
| Cash And Equivalents | 948.52 M | 2.7 B |
| Cash Per Share | 9.06 X | 5.01 X |
| Total Debt | 596.24 M | 5.32 B |
| Debt To Equity | 1.31 % | 48.70 % |
| Current Ratio | 8.08 X | 2.16 X |
| Book Value Per Share | 3.38 X | 1.93 K |
| Cash Flow From Operations | (73.34 M) | 971.22 M |
| Short Ratio | 3.16 X | 4.00 X |
| Earnings Per Share | (1.95) X | 3.12 X |
| Price To Earnings To Growth | (0.47) X | 4.89 X |
| Target Price | 27.33 | |
| Number Of Employees | 1.45 K | 18.84 K |
| Beta | 0.43 | -0.15 |
| Market Capitalization | 1.33 B | 19.03 B |
| Total Asset | 1.15 B | 29.47 B |
| Retained Earnings | (985.5 M) | 9.33 B |
| Working Capital | 855.29 M | 1.48 B |
Note: Disposition of 7693 shares by Moshe Giladi of Novocure at 83.77 subject to Rule 16b-3 [view details]
Novocure Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Novocure . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Novocure Buy or Sell Advice
When is the right time to buy or sell Novocure? Buying financial instruments such as Novocure Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 575.2M | 584.3M | 596.2M | 626.1M | Total Assets | 1.1B | 1.2B | 1.1B | 651.0M |
Use Investing Ideas to Build Portfolios
In addition to having Novocure in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cash Cows Thematic Idea Now
Cash Cows
Entities with stable and reliable earnings or profits, which allows them to pay consistent dividends to their shareholders. The Cash Cows theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cash Cows Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Novocure Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Novocure Stock, please use our How to Invest in Novocure guide.Note that the Novocure information on this page should be used as a complementary analysis to other Novocure's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Novocure Stock analysis
When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Novocure's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novocure. If investors know Novocure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novocure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share (1.95) | Revenue Per Share 4.787 | Quarterly Revenue Growth 0.042 | Return On Assets (0.12) |
The market value of Novocure is measured differently than its book value, which is the value of Novocure that is recorded on the company's balance sheet. Investors also form their own opinion of Novocure's value that differs from its market value or its book value, called intrinsic value, which is Novocure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novocure's market value can be influenced by many factors that don't directly affect Novocure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novocure's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novocure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novocure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.